Validation of methods for determining pediatric midazolam using wet whole blood and volumetric absorptive microsampling
Aim: Collection and quantitative analysis in dry blood using volumetric absorptive microsampling (VAMS™) potentially offers significant advantages over conventional wet whole blood analysis. This manuscript explores their use for pediatric sampling and explores additional considerations for the validation of the bioanalytical method. Results: HPLC-MS/MS methods for the determination of midazolam and its major metabolite 1-OH midazolam in both whole wet blood, and dry blood collected on VAMS were developed, validated, and used to support an observational clinical study to compare pharmacokinetic parameters in pediatric patients. Conclusion: Validation data met internationally accepted guideline criteria. A strong correlation was observed in calculated concentrations between wet and dry test samples, indicating that VAMS is a suitable technique for use in pediatric clinical studies.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Bioanalysis - 11(2019), 19 vom: 16. Okt., Seite 1737-1754 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Abu-Rabie, Paul [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 25.03.2020 Date Revised 25.03.2020 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.4155/bio-2019-0190 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM30223862X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM30223862X | ||
| 003 | DE-627 | ||
| 005 | 20231225110311.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4155/bio-2019-0190 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1007.xml |
| 035 | |a (DE-627)NLM30223862X | ||
| 035 | |a (NLM)31617393 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Abu-Rabie, Paul |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Validation of methods for determining pediatric midazolam using wet whole blood and volumetric absorptive microsampling |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.03.2020 | ||
| 500 | |a Date Revised 25.03.2020 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Aim: Collection and quantitative analysis in dry blood using volumetric absorptive microsampling (VAMS™) potentially offers significant advantages over conventional wet whole blood analysis. This manuscript explores their use for pediatric sampling and explores additional considerations for the validation of the bioanalytical method. Results: HPLC-MS/MS methods for the determination of midazolam and its major metabolite 1-OH midazolam in both whole wet blood, and dry blood collected on VAMS were developed, validated, and used to support an observational clinical study to compare pharmacokinetic parameters in pediatric patients. Conclusion: Validation data met internationally accepted guideline criteria. A strong correlation was observed in calculated concentrations between wet and dry test samples, indicating that VAMS is a suitable technique for use in pediatric clinical studies | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Validation Study | |
| 650 | 4 | |a LC–MS | |
| 650 | 4 | |a Mitra® microsamplers | |
| 650 | 4 | |a blood | |
| 650 | 4 | |a hematocrit | |
| 650 | 4 | |a microsampling | |
| 650 | 4 | |a pediatric | |
| 650 | 4 | |a pharmacokinetics | |
| 650 | 4 | |a volumetric absorptive sampling (VAMS) | |
| 650 | 4 | |a wet vs dry | |
| 650 | 7 | |a Hypnotics and Sedatives |2 NLM | |
| 650 | 7 | |a Midazolam |2 NLM | |
| 650 | 7 | |a R60L0SM5BC |2 NLM | |
| 700 | 1 | |a Neupane, Bikalpa |e verfasserin |4 aut | |
| 700 | 1 | |a Spooner, Neil |e verfasserin |4 aut | |
| 700 | 1 | |a Rudge, James |e verfasserin |4 aut | |
| 700 | 1 | |a Denniff, Philip |e verfasserin |4 aut | |
| 700 | 1 | |a Mulla, Hussain |e verfasserin |4 aut | |
| 700 | 1 | |a Pandya, Hitesh |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Bioanalysis |d 2009 |g 11(2019), 19 vom: 16. Okt., Seite 1737-1754 |w (DE-627)NLM196969840 |x 1757-6199 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2019 |g number:19 |g day:16 |g month:10 |g pages:1737-1754 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.4155/bio-2019-0190 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2019 |e 19 |b 16 |c 10 |h 1737-1754 | ||